A public offering of common stock has been launched by GenMark Diagnostics in hopes of obtaining $65 million. The company, which intends to grant a 30-day option for the underwriters to buy up to $9.75 million additional shares, plans to use the net proceeds to support its commercialization efforts and general corporate functions.
Public offering could pull in $65M for GenMark Diagnostics
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.